title: Adolescents' views and experiences of treatments for Type 2 diabetes: a qualitative study.
abstract: OBJECTIVE
  To explore adolescents' views and experiences of different treatments for Type 2 diabetes, in order to improve treatment concordance and consider how the current treatment pathway for adolescent Type 2 diabetes could be improved.
  
  
  METHODS
  In-depth interviews were held with 12 adolescents who had been diagnosed with Type 2 diabetes. Adolescents were sampled from a UK cohort study. Data were analysed thematically.
  
  
  RESULTS
  Interviewees struggled to maintain lifestyle changes. Insulin, metformin and liraglutide were described as effective but, in some cases, as resulting in side effects. Injected treatments were viewed less favourably than oral medications. Weight loss surgery was considered an acceptable treatment for obese adolescents who had tried other treatments for their diabetes. It was apparent that some adolescents had not been surprised by their diagnosis and did not fully appreciate the implications of having diabetes. It was also evident that some individuals had not told peers about their diagnosis due to fearing how they would react. Factors identified as improving treatment concordance included reminders and viewing treatment as effective and easy to take.
  
  
  CONCLUSIONS
  Adolescents want treatments that are effective, discrete, easy to take and do not make them different from their peers. As liraglutide was described as effective, and surgery viewed as acceptable in certain circumstances, greater consideration should be given to their potential role in treating adolescent Type 2 diabetes. Practitioners need to ensure that adolescents appreciate the implications of having diabetes and may want to address adolescents' concerns regarding how others view this condition.
authors.affiliation: School of Social and Community Medicine, University of Bristol, Bristol, UK.
authors.forename: K M
authors.initials: KM
authors.lastname: Turner
authors.forename: J
authors.initials: J
authors.lastname: Percival
authors.forename: D B
authors.initials: DB
authors.lastname: Dunger
authors.forename: T
authors.initials: T
authors.lastname: Olbers
authors.forename: T
authors.initials: T
authors.lastname: Barrett
authors.forename: J P H
authors.initials: JP
authors.lastname: Shield
mesh_terms: D000293:Adolescent; D001294:Attitude to Health; D050110:Bariatric Surgery / Q000009:adverse effects; D015992:Body Mass Index; D015331:Cohort Studies; D003131:Combined Modality Therapy / Q000009:adverse effects; D017281:Cost of Illness; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D003927:Diet, Diabetic / Q000009:adverse effects; D004038:Diet, Reducing / Q000009:adverse effects; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008019:Life Style; D008297:Male; D009043:Motor Activity; D009765:Obesity / Q000150:complications* / Q000178:diet therapy / Q000601:surgery / Q000628:therapy; D050177:Overweight / Q000150:complications* / Q000178:diet therapy / Q000628:therapy; D010349:Patient Compliance; D006113:United Kingdom
chemical_list: D007004:Hypoglycemic Agents